<DOC>
	<DOCNO>NCT01610154</DOCNO>
	<brief_summary>1 . The purpose study determine whether Sitagliptin therapy suppress glucagon release improve glucose control Chinese type 2 diabetic . 2 . There different effect Sitagliptin therapy blood glucose regulation , pancreatic alpha &amp; beta cell function different lean ( BMI &lt; 25 ) overweight ( BMI &gt; 25 ) Chinese type 2 diabetic . 3 . The purpose study determine whether glucagon release may contribute 30 % hyperglycemia Chinese type 2 diabetic .</brief_summary>
	<brief_title>Contribution Pancreatic αcells Function Blood Glucose Regulation Chinese Type 2 Diabetics― Effect Sitagliptin Glucagon Secretion , Insulin Secretion Insulin Resistance Chinese Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Age : 25~60 year 2 . Duration disease &lt; 3 year , drug treatment diabetes 3 . Newly diagnose type 2 diabetic patient ( fast plasma glucose &gt; 7.0mmol/L or/and 2h postprandial blood glucose &gt; 11.1mmol/L WHO 1999 ) 4 . Fasting plasma glucose &lt; 10 mmol/L 1 . Type 1 diabetes 2 . DKA , infection stress status 3 . Autoimmune disease 4 . Hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>glucagon</keyword>
	<keyword>dipeptidyl peptidase-4 inhibitor</keyword>
</DOC>